Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims - (Yahoo!Finance via NewsPoints Desk)

  • Sanofi and Regeneron Pharmaceuticals have filed a lawsuit seeking an order declaring that the eczema drug Dupixent does not infringe a patent held by Amgen, as reported Yahoo!Finance Tuesday.

  • The lawsuit is aiming to pre-empt expected litigation from Amgen, which has previously filed a lawsuit against the drugmakers regarding the cholesterol therapy Praluent.

  • "Sanofi and Regeneron wish to eliminate any potential obstacle Amgen might seek to raise against the planned US commercialisation of Dupixent," the drugmakers commented.

  • Analysts have estimated that Dupixent could amass sales of more than $5 billion by 2023.

  • The patent in question covers an experimental asthma therapy that Amgen abandoned in response to disappointing clinical trial results.

  • "We took this proactive step to protect the value of our innovative therapy Dupixent and ensure access of this important medicine for physicians and patients," Sanofi commented.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.